UK MHRA Approves Beyfortus to Prevent RSV in newborns
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Beyfortus (nirsevimab) to treat respiratory syncytial virus (RSV) lower respiratory tract disease in the infants and newborns during their first RSV season. This approval come after the European Commission approve Beyfortus earlier this month. According to studies, about 90 percent of children by 2 […]
Continue Reading